The ARA-290 trial literature is unusually clean about timing: the Phase 2 studies dosed for 28 days, then measured nerve and symptom outcomes — and in the sarcoidosis trial, tracked them out to 16 weeks. The timeline below reflects what those trials documented, not a guaranteed schedule.
Research-context information only. ARA-290 (cibinetide) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What follows is anchored to the 4 mg/day, 28-day protocol the Phase 2 trials used. Individual variation is large, and nerve repair is inherently slow — these are population-level trial observations.
Week 1
The published trials did not report dramatic early changes in the first week. ARA-290's mechanism is tissue-protective and regenerative rather than analgesic in the acute sense, so the trial data does not describe immediate pain relief. Investigators reported injection-site reactions as the most common early event.
Weeks 2-4
This is the active dosing window. By the end of the 28-day course, the dose-ranging sarcoidosis trial reported a significant placebo-corrected increase in corneal nerve fiber area at the 4 mg dose, plus a significant rise in skin regenerating nerve fibers (Culver et al., 2017). The earlier 2013 trial similarly reported increased corneal small nerve fiber density and improved neuropathic symptoms over the 28-day course (Dahan et al., 2013).
In the type 2 diabetes trial, 4 mg/day for 28 days produced reductions in HbA1c and improved lipid markers by the end of the course (Brines et al., 2015).
Weeks 5-8
Dosing has typically stopped by this point (the trials ran 28-day courses). The type 2 diabetes trial reported that metabolic improvements persisted through a 56-day observation period — roughly four weeks after the last dose (Brines et al., 2015). This is the window where the trials suggest effects can carry past the dosing course rather than reverse immediately.
Weeks 9-16
The 2013 sarcoidosis trial followed patients out to 16 weeks and reported that several symptom improvements were sustained at that point, well after the 28-day course ended (Dahan et al., 2013). Durability beyond 16 weeks is not characterized in the published literature.
Ready to buy? Compare verified vendors on our best ARA-290 sources page, or browse all coupon codes for up to 50% off.
